{"id":"W3095354231","doi":"10.1182/blood-2020-136198","title":"Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada); BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); CD47; Hematologic Neoplasms; Oncology; Leukapheresis; Internal medicine; Intensive care medicine; Cancer; Receptor; Stem cell; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00453941,0.0009731441,0.001509813,0.0004774011,0.0003984497,0.001576065,0.0009658488,0.001477975,0.005456213],"category_scores_gemma":[0.002857443,0.0004901824,0.001297858,0.0006914911,0.0003768482,0.0009054108,0.0004512371,0.002338987,0.00115654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009962071,"about_ca_system_score_gemma":0.002047149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009945722,"about_ca_topic_score_gemma":0.003705061,"domain_scores_codex":[0.99854,0.0007839841,0.0001126993,0.0001165398,0.0002718432,0.0001748215],"domain_scores_gemma":[0.9982004,0.0004078537,0.0004898753,0.0001493386,0.0002836227,0.0004688473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1794588,0.02060165,0.01955235,0.002979986,0.002460614,0.0005706314,0.0005572958,0.005469985,0.07816304,0.0009915119,0.07289504,0.6162991],"study_design_scores_gemma":[0.251988,0.3740308,0.07496487,0.000992105,0.004072556,0.002024253,0.0002798697,0.002903306,0.02545624,0.00162324,0.2615363,0.0001284934],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8414906,0.05982647,0.006394784,0.01140438,0.001260698,0.01631445,0.03032932,0.001417532,0.03156171],"genre_scores_gemma":[0.8503468,0.03525569,0.01730499,0.01592772,0.001331636,0.01726762,0.0480809,0.0003635516,0.01412112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005456213,"threshold_uncertainty_score":0.02400702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0196920499174189,"score_gpt":0.2409773554635876,"score_spread":0.2212853055461687,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}